TPOXX

Phase 3Completed

0 views this week 0 watching💤 Quiet

Interest: 30/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Smallpox

Conditions

Smallpox

Trial Timeline

Mar 29, 2022 → May 12, 2023

NCT ID

NCT04971109

About TPOXX

TPOXX is a phase 3 stage product being developed by SIGA Technologies for Smallpox. The current trial status is completed. This product is registered under clinical trial identifier NCT04971109. Target conditions include Smallpox.

What happened to similar drugs?

3 of 7 similar drugs in Smallpox were approved

Approved (3) Terminated (0) Active (4)

✅Vaccination with ACAM2000Emergent BioSolutionsApproved

✅Tecovirimat + sevelamer carbonate oral tablet + sucroferric oxyhydroxide chewable tablet + calcium acetate oral tablet + Lanthanum Carbonate Chewable TabletSIGA TechnologiesApproved

✅TpoxxSIGA TechnologiesApproved

🔄FD MVA-BNBavarian NordicPhase 3

🔄IMVAMUNE®Bavarian NordicPhase 3

🔄ACAM2000Emergent BioSolutionsPhase 3

🔄tecovirimatSIGA TechnologiesPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04971109	Phase 3	Completed	Mar 29, 2022	May 12, 2023	Smallpox
NCT04392739	Approved	Completed	Jul 19, 2019	Dec 5, 2019	Smallpox

Competing Products

20 competing products in Smallpox

See all competitors

Product	Company	Stage	Hype Score
mRNA-1769	Moderna	Phase 2	0
Smallpox vaccine, LISTER strain, from chick embryo cells	Sanofi	Phase 2	35
MVA (smallpox vaccine)	Sanofi	Phase 1	21
ACAM3000 MVA Vaccine	Sanofi	Phase 1	29
MVA Smallpox vaccine + Placebo	Sanofi	Phase 2	35
ACAM1000 + vaccinia virus (calf lymph) smallpox vaccine: Dryvax	Sanofi	Phase 2	27
IMVAMUNE (MVA-BN)	Bavarian Nordic	Phase 2	32
MVA-BN	Bavarian Nordic	Phase 1	26
IMVAMUNE®	Bavarian Nordic	Phase 2	32
LF formulation of IMVAMUNE® + FD formulation of IMVAMUNE®	Bavarian Nordic	Phase 2	32
IMVAMUNE + IMVAMUNE	Bavarian Nordic	Phase 2	32
FD MVA-BN	Bavarian Nordic	Phase 3	37
IMVAMUNE®	Bavarian Nordic	Phase 3	37
IMVAMUNE + IMVAMUNE	Bavarian Nordic	Phase 2	32
MVA-BN® (IMVAMUNE) + Placebo	Bavarian Nordic	Phase 2	32
Elstree-BN	Bavarian Nordic	Phase 1	26
ACAM2000	Emergent BioSolutions	Phase 3	30
VIGIV	Emergent BioSolutions	Pre-clinical	23
ACAM2000® smallpox vaccine	Emergent BioSolutions	Pre-clinical	16
Brincidofovir	Emergent BioSolutions	Phase 1	19